Long-term outcomes of second-line versus later-line zanubrutinib treatment in patients with relapsed/refractory mantle cell lymphoma: An updated pooled analysis.
Song Y, Zhou K, Zou D, Li D, Hu J, Yang H, Zhang H, Ji J, Xu W, Jin J, Lv F, Feng R, Gao S, Zhou D, Tam CS, Simpson D, Wang M, Phillips TJ, Opat S, Fang C, Sun S, Zhu J.
Song Y, et al. Among authors: opat s.
Cancer Med. 2023 Sep;12(18):18643-18653. doi: 10.1002/cam4.6473. Epub 2023 Sep 14.
Cancer Med. 2023.
PMID: 37705497
Free PMC article.